NMTC vs BSX

For growth investors, NeuroOne Medical Technologies Corporation (NMTC) is the stronger pick with 250.

4% revenue growth year-over-year, versus 19. 9% for Boston Scientific Corporation (BSX). Boston Scientific Corporation (BSX) offers the better valuation at 29. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate NeuroOne Medical Technologies Corporation (NMTC) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -88. 8% for NeuroOne Medical Technologies Corporation (NMTC). Over 10 years, the gap is even starker: BSX returned +155. 5% versus NMTC's -93. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus NeuroOne Medical Technologies Corporation's 0. 74β — meaning NMTC is approximately 116% more volatile than BSX relative to the S&P 500. On balance sheet safety, NeuroOne Medical Technologies Corporation (NMTC) carries a lower debt/equity ratio of 4% versus 51% for Boston Scientific Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NeuroOne Medical Technologies Corporation (NMTC) is pulling ahead at 250.

4% versus 19. 9% for Boston Scientific Corporation (BSX). On earnings-per-share growth, the picture is similar: NeuroOne Medical Technologies Corporation grew EPS 80. 4% year-over-year, compared to 55. 2% for Boston Scientific Corporation. Over a 3-year CAGR, NMTC leads at 313. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus -29. 8% for NeuroOne Medical Technologies Corporation — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus -34. 9% for NMTC. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BSX: 61.

4% to $91. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Boston Scientific Corporation (BSX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

34), +155. 5% 10Y return). Both have compounded well over 10 years (BSX: +155. 5%, NMTC: -93. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.